PRCL-02 / PRCL Research - LARVOL DELTA

Targeting Calcium Release-activated Calcium Channel Is Not Sufficient to Prevent Rejection in Nonhuman Primate Kidney Transplantation. (PubMed, Transplantation) - "We conclude that, in this nonhuman primate model of kidney transplantation, PRCL-02 demonstrated evidence of in vivo immunosuppressive activity but was inferior to tacrolimus treatment with respect to suppressing immune transplant rejection."

Journal • Immune Modulation • Immunology • Inflammation • Nephrology • Transplantation

The safety, tolerability and pharmacokinetics of prcl‐02 in healthy volunteers and patients with chronic plaque psoriasis (SPIN 2019) - "No clinically significant safety or tolerability concerns were identified with PRCL-02. There were no SAEs. Most AEs were mild and, of those considered related to PRCL-02, were reported once with no dose relationship observed.In Part A, PRCL-02 median tmax was ˜4 h across doses."

Clinical • PK/PD data • Dermatology • Dermatopathology • Immunology • Psoriasis

A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - P2a; N=92; Completed; Sponsor: PRCL Research Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion

A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - P2a; N=92; Active, not recruiting; Sponsor: PRCL Research Inc.; Trial completion date: Jun 2019 ➔ Sep 2019

Clinical • Trial completion date

A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - P2a; N=89; Active, not recruiting; Sponsor: PRCL Research Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed